IDE275 (GSK959) development is progressing into First-in-Human Phase 1 clinical trial(s) for the treatment of MSI-High solid tumors, representing IDEAYA's 5th potential first-in-class clinical program MSI-High prevalence in endometrial, colorectal, and gastric cancers is ~31%, 20%, and 19%, respectively, highlighting the market potential of IDE275 (GSK959) IDEAYA to receive a $7 million payment for IND acceptance, and potential future aggregate milestones of up to $950 million. IDEAYA has a 50/50 US Profit ...

GSK plc (NYSE: GSK ) is a biopharmaceutical company with a long history of driving innovation in developing vaccines, specialty medicines, and general healthcare. The company has important products such as Shingrix and Arexvy in its vaccine segment. GSK also presents a strong My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, ...

GSK plc (GSK) announced that the FDA has accepted its new drug application (NDA) seeking approval for its investigational, first-in-class oral antibiotic, gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. With the FDA granting a priority review to the NDA, a decision from the regulatory body is expected on March 26, 2025. If approved, gepotidacin could become the first in a new class of oral antibiotic medicines to be approved for treating uUTIs in mor ...

Group 1: Novavax Update - The FDA has placed a clinical hold on Novavax's combination and standalone influenza shot [1] - Novavax's stock has dropped 17.7% to $10.36, nearing its lowest close since mid-May, although it remains up 115% in 2024 [2] Group 2: Moderna's Market Position - Moderna's shares are trading at $57.42, close to a four-year low of $55.70, reflecting a year-to-date decline of 42.2% [3] - The decline is attributed to a significant budget cut and lowered expectations for its RSV drug, with plans to regain market share by 2025 [3] Group 3: GSK Developments - GSK's stock is up 0.5% to $39.17 following the FDA's acceptance of its new drug application for urinary tract infections [4] - The company received FDA approval for its RSV vaccine in the summer, although the stock did not react significantly, and shares are 5.8% higher in 2024 [4]

GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of John Baldoni, Ph.D., to its Scientific Advisory Board. Dr. Baldoni brings over four decades of experience in the pharmaceutical industry, including leadership roles in scientifi ...

Share price of the British pharmaceutical company GSK (NYSE: GSK ) has gone nowhere since I last wrote about at the end of July. Until yesterday, that is, when it spiked by ~6% following news that the company had Manika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her investing group, Green Growth Giants ...

KEY TAKEAWAYS GSK shares in London jumped 5% Thursday after the British pharmaceutical giant said it has resolved most of the U.S. lawsuits it faced around claims that its discontinued heartburn medicine Zantac causes cancer. The London-listed firm said it had struck agreements to resolve 93%, or about 80,000, of the pending Zantac lawsuits in the U.S. and will make a total payment of up to $2.2 billion to settle them. GSK said the plaintiffs are unanimously recommending their clients accept the settlement. ...

In a swarm of lawsuits, the company stood accused of selling a potentially cancer-causing medication. Thanks largely to news of a crucial legal settlement, GSK (GSK 5.84%) was one of the better-performing big pharma stocks on Wednesday. Relieved investors showed their appreciation by collectively bidding the company's shares up by 5.8% on the day, a performance that easily eclipsed the 0.7% rise of the benchmark S&P 500 index. $2.2 billion-plus in settlements That news concerns a discontinued version of GSK ...

GlaxoSmithKline (GSK, Financial) has agreed to a substantial settlement in connection with lawsuits related to its Zantac product in U.S. state courts. The company announced that it reached settlements with 10 plaintiff firms, which represent a significant 93% of the cases filed against the pharmaceutical company regarding Zantac. The total settlement amount is up to $2.2 billion. ...

GSK (GSK, Financial) announced that its respiratory syncytial virus (RSV) vaccine has shown protective benefits for three quarters following vaccination. The cumulative efficacy of the vaccine, adjusted for seasonal factors, stands at 62.9% for the elderly. This data is crucial for advisory panels, doctors, and patients when deciding which RSV vaccine to choose, as GSK faces strong competition from Pfizer (PFE) and Moderna (MRNA). The vaccine is approved for all adults aged 60 and above in the US and EU, as ...